Home > Clinical Trials
Check All Search

Saved trials

연구종결
KCT0010330
비타민K비의존성 경구용 항응고제를 사용하는 비판막성 심방세동 환자에서 올메사르탄 병용 사용군 대비 텔미사르탄 병용 사용군의 출혈 위험을 평가하는 후향적 코호트 연구
18,252 Enrollment(s)
1 Study location(s)
관찰연구 (None)
연구종결
KCT0009530
건강한 성인을 대상으로 보중익기탕, 청상견통탕 및 이진탕이 에독사반의 약동학 및 약력학에 미치는 영향을 평가하기 위한 임상시험
30 Enrollment(s)
1 Study location(s)
중재연구 (None)
RECRUITING
NCT06551220
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns
800 Enrollment(s)
23 Study location(s)
OBSERVATIONAL (None)
Metastatic Breast Cancer
NOT_YET_RECRUITING
NCT06711978
Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors
66 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (NA)
CIPN


CIPN - Chemotherapy-Induced Peripheral Neuropathy


CIPN in Adjuvant Breast Cancer Patients


Duloxetine


Mirogabalin
NOT_YET_RECRUITING
NCT06608472
Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
292 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE3)
Essential Arterial Hypertension
RECRUITING
NCT06102824
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
252 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
HER2-negative Breast Cancer


Advanced Breast Cancer
RECRUITING
NCT05824975
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
358 Enrollment(s)
11 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Advanced Solid Tumor


Metastatic Solid Tumor


Soft Tissue Sarcoma (STS)


Platinum-resistant Ovarian Cancer (PROC)


Hepatocellular Carcinoma (HCC)


Colorectal Cancer (CRC)


HER2 Negative Breast Cancer


Cutaneous Melanoma


Renal Cell Carcinoma (RCC)
COMPLETED
NCT04989816
Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens
95 Enrollment(s)
24 Study location(s)
INTERVENTIONAL (PHASE2)
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma